Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H28N6O3 |
| Molecular Weight | 400.4747 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(CNC2=C3N=CN(C(C)C)C3=NC(=N2)N(CCO)CCO)C=C1
InChI
InChIKey=NQVIIUBWMBHLOZ-UHFFFAOYSA-N
InChI=1S/C20H28N6O3/c1-14(2)26-13-22-17-18(21-12-15-4-6-16(29-3)7-5-15)23-20(24-19(17)26)25(8-10-27)9-11-28/h4-7,13-14,27-28H,8-12H2,1-3H3,(H,21,23,24)
| Molecular Formula | C20H28N6O3 |
| Molecular Weight | 400.4747 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25175461 |
https://www.ncbi.nlm.nih.gov/pubmed/26986210
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25175461 |
https://www.ncbi.nlm.nih.gov/pubmed/26986210
CVT 313 is the lead compound in a series of small molecule cell cycle inhibitors that inhibit cyclin-dependent kinase 2 (CDK2). It was in development with CV Therapeutics in the USA. CVT 313, in combination with drug delivery catheters and as coatings on endoluminal stents, may have potential in the prevention of restenosis. In February 1998, CV Therapeutics signed a research agreement with The Cleveland Clinic Foundation for the preclinical testing of CVT 313. In February 1999 CV Therapeutics announced the granting of a patent for purine inhibitors of CDK2 by the USA Patent and Trademark Office. No recent development of CVT 313 has been reported.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. | 2007 Dec 18 |
|
| Retinoblastoma protein modulates the inverse relationship between cellular proliferation and elastogenesis. | 2011 Oct 21 |
|
| Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. | 2011 Oct 30 |
|
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. | 2013 Apr 15 |
Patents
Sample Use Guides
The exposure of the denuded carotid artery to the hydrochloride salt of CVT-313 in saline solution (1.25 mg/kg) for 15 min under pressure, reduced neointima formation by 80%. Two lower doses of CVT-313 (0.75 and 0.25 mg/kg) were less efficacious, reducing mean neointimal area by about 30%. Representative sections from experimental rat carotid arteries 14 days after endothelial denudation demonstrate the efficacy of CVT-313 in blocking restenosis in the rat carotid model.
Route of Administration:
Intra-arterial
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:34:34 GMT 2023
by
admin
on
Sat Dec 16 09:34:34 GMT 2023
|
| Record UNII |
T5490K8I7S
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
6918386
Created by
admin on Sat Dec 16 09:34:34 GMT 2023 , Edited by admin on Sat Dec 16 09:34:34 GMT 2023
|
PRIMARY | |||
|
DTXSID30173812
Created by
admin on Sat Dec 16 09:34:34 GMT 2023 , Edited by admin on Sat Dec 16 09:34:34 GMT 2023
|
PRIMARY | |||
|
T5490K8I7S
Created by
admin on Sat Dec 16 09:34:34 GMT 2023 , Edited by admin on Sat Dec 16 09:34:34 GMT 2023
|
PRIMARY | |||
|
199986-75-9
Created by
admin on Sat Dec 16 09:34:34 GMT 2023 , Edited by admin on Sat Dec 16 09:34:34 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
